Ad26 EBOV vaccine

Drug Profile

Ad26 EBOV vaccine

Alternative Names: Ad26 EBOV vaccine - Crucell/NIH; Ad26 EBOV vaccine - NIH/Crucell; Ad26-ZEBOV - Crucell/NIH; Ad26-ZEBOV - NIH/Crucell; Ad26.ZEBOV - Crucell/NIH; Ad26.ZEBOV - NIH/Crucell; Ebola virus vaccine - Crucell/NIH; Ebola virus vaccine - NIH/Crucell

Latest Information Update: 23 Dec 2016

Price : $50

At a glance

  • Originator Crucell; National Institutes of Health (USA)
  • Developer Bavarian Nordic; Crucell; National Institutes of Health (USA)
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ebola virus infections

Most Recent Events

  • 01 Sep 2016 Crucell Holland completes a phase I trial in Ebola virus infections (Prevention) in Tanzania and Uganda (IM) (NCT02376400)
  • 01 Sep 2016 National Institute of Allergy and Infectious Diseases (NIAID) plans a phase I trial for Ebola virus infection (In volunteers) in USA (NCT02891980)
  • 26 Aug 2016 National Institute of Allergy and Infectious Diseases plans a phase II trial for Ebola virus infections (Prevention) in USA (IM) (NCT02876328)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top